ReviewViruses2023
Recent Developments in Human Papillomavirus (HPV) Vaccinology.
Review in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
118 citing papers in PubMed, 4 syntheses or guidelines pooled it, 155 citations in OpenAlex.
- Determinants of human papillomavirus vaccination uptake in Nigeria: a mixed-methods systematic review.BMC public health · 2026Pooled it
- Impact of HPV vaccine on CIN2+ recurrence after conization: a systematic review and meta-analysis of vaccination timing, valency and surgical margins.Frontiers in oncology · 2026Pooled it
- Perspectives of HPV vaccine decision-making among young adults: A qualitative systematic review and evidence synthesis.PloS one · 2025Pooled it
- Pooled it
- Subtype-specific mechanisms of lipid metabolism in gynecological malignancies and novel targeted intervention strategies (Review).Oncology letters · 2026Review
- Adjuvant human papillomavirus vaccination after excisional treatment for cervical precancer.Turkish journal of obstetrics and gynecology · 2026Article
- Evaluation of Knowledge About Human Papillomavirus and Vaccination Among Women Screened for Cervical Cancer.The International journal of health planning and management · 2026Article
- Experimental Analysis of HPV16 L1/L2 Chimeric VLP Internalization by Human Peripheral Blood Leukocytes.International journal of molecular sciences · 2026Article
- Article
- Article
- Global trends and insights in cervical cancer research: a bibliometric analysis from 2000 to 2024.Reproduction & fertility · 2026Article
- Article
- Epidemiological characteristics and genotype distribution of low-risk human papillomavirus infection among women in Jingzhou, Central China: a cross-sectional study.BMC infectious diseases · 2026Article
- Genomic determinants and an exploratory prognostic model for immunotherapy outcomes in recurrent or metastatic cervical cancer.The oncologist · 2026Article
- Identification of Conserved Cross-Reactive B-Cell Epitopes in CPV1 and CPV2 L1 Proteins with Vaccine Potential.Vaccines · 2026Article
- Factors Related to Parental Intention to Vaccinate Young Adolescent Boys Against Human Papillomavirus in Taiwan.The Kaohsiung journal of medical sciences · 2026Article
- Is It Time to Reassess the Target Age of Human Papillomavirus Vaccination Globally?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- High-risk human papillomavirus genotype distribution, cytological abnormalities, and associated factors among Ethiopian women: a multicenter study.Microbiology spectrum · 2026Article
- Integrative bioinformatics approach to the mRNA vaccine development for the human papillomavirus using the capsid protein.Biology direct · 2026Article
- Anal Dysplasia: Epidemiology, Risk Factors, and Progression to Malignancy.Clinics in colon and rectal surgery · 2026Review
58 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV) is causally associated with 5% of cancers, including cancers of the cervix, penis, vulva, vagina, anus and oropharynx. The most carcinogenic HPV is HPV-16, which dominates the types causing cancer. There is also sufficient evidence that HPV types 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 cause cervical cancer. The L1 protein, which, when assembled into virus-like particles, induces HPV-type-specific neutralising antibodies, forms the basis of all commercial HPV vaccines. There are six licensed prophylactic HPV vaccines: three bivalent, two quadrivalent and one nonavalent vaccine. The bivalent vaccines protect from HPV types 16 and 18, which are associated with more than 70% of cervical cancers. Prophylactic vaccination targets children before sexual debut, but there are now catch-up campaigns, which have also been shown to be beneficial in reducing HPV infection and disease. HPV vaccination of adults after treatment for cervical lesions or recurrent respiratory papillomatosis has impacted recurrence. Gender-neutral vaccination will improve herd immunity and prevent infection in men and women. HPV vaccines are immunogenic in people living with HIV, but more research is needed on the long-term impact of vaccination and to determine whether further boosters are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.